1. Home
  2. Companies
  3. ACW
  4. Material Events

Actinogen Medical (ASX:ACW) — Material Events

ASX:ACW · 21 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 21 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
21
Actinogen Completes Enrollment in Pivotal Alzheimer’s Trial, Eyes November 2026 ResultsMedium
Actinogen completes enrollment in XanaMIA Alzheimer's trial; final results due Nov 2026
18 Dec 2025 ·Clinical Trial Update ·85
Actinogen Surpasses Recruitment Target, Eyes November for XanaMIA Trial ResultsMedium
Actinogen completes XanaMIA trial recruitment, positive interim results, prepares for open-label extension and strengthens cash position
30 Jan 2026 ·Quarterly Activity Report and Appendix 4C ·85
Actinogen Medical Advances Alzheimer's Drug with Pivotal Trial Results Due NovemberHigh
Actinogen Medical FY2026 results highlight imminent Alzheimer's trial data and regulatory progress
27 Aug 2026 ·Full Year Financial Results and Corporate Update ·85
Actinogen Secures FDA Nod on Xanamem’s Alzheimer’s Trial BlueprintMedium
Actinogen secures FDA agreement on Xanamem development pathway for Alzheimer's approval
15 Sept 2025 ·Regulatory Update ·85
Actinogen Accelerates Alzheimer’s Trial and Secures FDA Pathway Amid Funding BoostMedium
Actinogen accelerates Alzheimer's trial enrolment, updates FDA pathway, secures funding runway to mid 2026
23 Oct 2025 ·Quarterly Activity Report and Appendix 4C ·85
Actinogen’s XanaMIA Trial Clears Key Hurdle with Positive Interim ReviewMedium
Actinogen's XanaMIA Alzheimer's Trial Recommended to Continue After Positive Interim Analysis
30 Jan 2026 ·Clinical Trial Update ·85
Actinogen Secures $16.8M to Power Key Alzheimer’s Trial Through 2026Medium
Actinogen Medical raises $16.8M to fund pivotal Alzheimer's trial and 2026 initiatives
27 Feb 2026 ·Capital Raising ·85
Actinogen’s XanaMIA Trial Clears Third Safety Review Ahead of November ResultsMedium
Actinogen Medical's XanaMIA Alzheimer's trial receives third positive safety recommendation; final results due November 2026
18 June 2026 ·Clinical Trial Update ·85
Actinogen Secures $17M to Power Alzheimer’s Trial After Positive Interim DataHigh
Actinogen raises $17M to advance XanaMIA Alzheimer’s trial after positive interim results
2 Feb 2026 ·Capital Raising ·85
Actinogen Extends Cash Runway After Positive XanaMIA Interim AnalysisHigh
Actinogen Medical reports positive interim XanaMIA trial results, $16.8M capital raise, and extended cash runway
29 Apr 2026 ·Quarterly Activity Report and Appendix 4C ·85
Actinogen Accelerates Alzheimer’s Trial with Expanded Enrollment and Early Screening CloseMedium
Actinogen Medical accelerates Alzheimer's trial enrolment, final results expected mid Q4 2026
20 Oct 2025 ·Clinical Trial Update ·85
Actinogen Advances Alzheimer's Trial with Positive Regulatory Feedback and Strong Cash PositionMedium
Actinogen advances Alzheimer's trial with positive regulatory feedback and strong cash position
30 July 2026 ·Quarterly Activity Report and Appendix 4C ·85
Actinogen Secures Clear EMA Pathway for Alzheimer’s Drug XanamemMedium
Actinogen secures positive EMA advice aligned with FDA for Alzheimer's drug Xanamem development
28 May 2026 ·Regulatory Update ·85
Actinogen’s Alzheimer’s Trial Clears Safety Hurdle, Eyes January Efficacy ReviewMedium
Actinogen Medical's Alzheimer's trial continues after positive safety review by Data Monitoring Committee
12 Nov 2025 ·Clinical Trial Update ·80
Actinogen Medical Secures $4.77 Million Underwriting Ahead of Key Alzheimer’s ReadoutMedium
Actinogen Medical secures $4.77 million through full underwriting of unlisted options ahead of pivotal Alzheimer’s trial results
1 Sept 2026 ·Capital Raising ·75
Actinogen Medical’s Xanamem Shows Antidepressant Promise in Tough Depression TrialMedium
Actinogen Medical publishes positive phase 2 trial results for Xanamem in depression
20 July 2026 ·Clinical Trial Results Publication ·75
Actinogen Launches Open-Label Phase to Extend Xanamem Alzheimer’s TrialMedium
Actinogen starts open-label extension of XanaMIA Alzheimer's trial with Xanamem
1 Apr 2026 ·Clinical Trial Update ·75
Actinogen Secures $4.3m Boost for Alzheimer’s Trial Ahead of Key DataMedium
Actinogen Medical secures $4.3m R&D tax incentive funding to support Alzheimer's trial
27 Jan 2026 ·Funding Announcement ·75
Actinogen Medical Nets $5.5m R&D Rebate, Fuels Alzheimer’s Trial MomentumMedium
Actinogen Medical secures $5.5m R&D tax rebate, advancing Alzheimer's drug trials
15 Oct 2025 ·ASX Announcement ·75
Actinogen Secures $7.36m R&D Rebate as Alzheimer’s Trial AdvancesMedium
Actinogen Medical receives further $1.87m R&D tax rebate; Alzheimer's trial progressing well
11 Feb 2026 ·ASX Announcement ·75
Actinogen Medical Secures Additional $1.87M R&D Rebate Boosting FY25 FundingMedium
Actinogen Medical secures additional $1.87M R&D rebate, total FY25 rebate $7.36M
20 Oct 2025 ·ASX Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.